Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/X-Linked Hypophosphatemia

Endocrine & Hormonal

X-Linked Hypophosphatemia (XLH) Clinical Trials

Also called XLH, X-Linked Hypophosphatemic Rickets, XLHR, Phosphate Diabetes, Vitamin D-Resistant Rickets

X-Linked Hypophosphatemia occurs when the body produces too much of a hormone called FGF23, which causes the kidneys to waste phosphate. This disrupts bone mineralization and leads to rickets in children and ongoing bone and joint problems in adults. The condition affects both skeletal development and dental health, with children commonly experiencing delayed growth, bone deformities, and dental complications.

In plain words, X-linked hypophosphatemia is a rare genetic bone disorder where the body loses too much phosphate, a mineral bones need to stay strong. Children often develop bowed legs and short height, while adults may have ongoing bone and muscle pain.

Get an email when new X-Linked Hypophosphatemia trials open or the FDA decides. Get alerts

X-Linked Hypophosphatemia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 4 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Crysvita · Vitamin D

X-Linked Hypophosphatemia has 2 FDA-approved medicines, 5 open or active clinical trials (4 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for X-Linked Hypophosphatemia

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about X-Linked Hypophosphatemia

Traditionally, XLH was managed with phosphate supplements and high-dose vitamin D, requiring frequent monitoring and multiple daily doses. Targeted therapy with burosumab offers a fundamentally different approach by blocking excess FGF23, the hormone behind the phosphate loss, rather than replacing phosphate by mouth. This treatment leads to better phosphate levels, improved bone healing, reduced pain, and improved physical function.

Keep reading about X-Linked Hypophosphatemia

Early diagnosis and treatment make a significant difference in preventing severe bone deformities and improving quality of life. Many patients experience substantial improvements in mobility and pain levels when started on appropriate therapy.

What are the symptoms of X-Linked Hypophosphatemia?

These are common symptoms of X-Linked Hypophosphatemia, and how strong they are varies from person to person.

  • Bowed legs or knee deformities
  • Short stature or slowed growth
  • Bone and muscle pain or weakness
  • Delayed walking or mobility problems in children
  • Dental problems including recurrent tooth abscesses
  • Joint stiffness and fractures in adults

Who gets X-Linked Hypophosphatemia?

XLH is caused by mutations in the PHEX gene on the X chromosome and typically appears in infancy or early childhood, usually between 12 and 18 months when children begin weight-bearing activities. Females with 1 PHEX variant usually have signs and symptoms similar to those in males, according to MedlinePlus Genetics, and severity varies widely even within a family. It affects people of all ethnicities.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for X-Linked Hypophosphatemia?

There are currently 2 FDA-approved medications for X-Linked Hypophosphatemia.

burosumab
Kyowa Kirin, Inc.
Search
Vitamin D
ergocalciferol
REMEDYREPACK INC.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for X-Linked Hypophosphatemia treatment

Charity funds and drugmaker programs for X-Linked Hypophosphatemia, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · The Assistance Fund
    Hypophosphatemia fund
    Open

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 20, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for X-Linked Hypophosphatemia, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for X-Linked Hypophosphatemia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted X-Linked Hypophosphatemia resources

Reputable organizations and medical references for learning more about X-Linked Hypophosphatemia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for X-Linked Hypophosphatemia

Use this X-Linked Hypophosphatemia clinical trial finder to see the 4 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 3 test a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

5 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1/2Recently updatedNCT06525636

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Intervention: KK8123

Sponsor: Kyowa Kirin Co., Ltd. · Kyowa Kirin, Inc.

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.

Ages 18 Years to 65 Years
Started Oct 2024Updated 2 weeks agoEst. Jun 2030 (~3y 6m)
RecruitingTreatment trialUpdated a few months agoNCT06921720

Phosphorus-31 Spectroscopy in Phosphate Diabetes

Intervention: intra-muscular ATP values in phosphate diabetes, intra-muscular phosphate values in phosphate diabetes

Sponsor: Hospices Civils de Lyon

Phosphate diabetes is defined by urinary phosphate wasting due to impaired tubular reabsorption. It can be classified based on either a genetic or acquired origin. Chronic hypophosphatemia causes rickets in children, leading to growth disorders, bone deformities, and bone pain. I...

Ages 10 Years+2 locations
Started May 2025Updated 4 months agoEst. May 2028 (~1y 5m)
RecruitingObservational study, no treatment givenUpdated a few months agoNCT03193476

Registry for Patients With X-Linked Hypophosphatemia

Sponsor: Kyowa Kirin Pharmaceutical Development Ltd · IQVIA Pty Ltd

This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). The main objective of this XLH Registry is to collect data to characterise the treatment, progression and long-term outcomes of XLH in both adult and paediatric settings.

Ages not specified
Started Sep 2017Updated 4 months agoEst. Feb 2029 (~2y 2m)
Not yet recruitingTreatment trialUpdated a few months agoNCT07666269

Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis

Intervention: intra-oral 3D optical impression

Sponsor: University Hospital, Bordeaux

MOSAIC aims to determine whether oro-dental morphological anomalies, particularly palatal morphology, associated with rare bone and cartilage diseases can be precisely characterized using 3D digital models analysed through geometric morphometrics. The study will also evaluate whe...

Ages 18 Years+1 location
Expected to start Sep 2026Updated 5 months agoEst. Mar 2028 (~1y 3m)
RecruitingObservational study, no treatment givenNo updates in a whileNCT07183579

Effective Dosing of Burosumab in XLH

Sponsor: University of Nottingham

X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells. Low phosphate leads to soft bones (rickets). Patients...

Ages 2 Years to 18 Years1 location
Started Nov 2025Updated 6 months agoEst. Jul 2026
Find X-Linked Hypophosphatemia trials near you, ranked by distance →
Active trial locations5 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Jun 2030
2021
2023
2025
2027
2029
now
Phase 1
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about X-Linked Hypophosphatemia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a X-Linked Hypophosphatemia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

X-Linked Hypophosphatemia patient communities

Facebook groups, Reddit communities and YouTube channels where X-Linked Hypophosphatemia patients, caregivers and advocacy groups talk.

Companies developing X-Linked Hypophosphatemia treatments

Drugmakers that list X-Linked Hypophosphatemia in their rare disease portfolio, 2 in all.

Questions people ask about X-Linked Hypophosphatemia